Clinical Trial Update: An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE) [Phase 3]

View source ↗

Summary

Open-label extension trial assessing long-term safety of KVD900 (sebentralstat) for on-demand treatment of angioedema attacks in adolescents and adults with her…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• KVD900 (Sebetralstat)

Snippet

Sponsor: KalVista Pharmaceuticals, Ltd. | Conditions: Hereditary Angioedema | Phase 3 | Status: COMPLETED